Back to search

Article

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

2020-11-04

Abstract excerpt

Background: Recent randomized trials have demonstrated improvements in overall survival (OS) for the BCL-2 inhibitor venetoclax (VEN) in combination with azacitidine and low dose cytarabine in older unfit patients with AML. Pre-clinical studies identified BAX deficiency as a potential mechanism of VEN resistance in AML, but this has not been observed in patients to date (Chen, Cancer Disc 2019). Methods: Patient s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9301f4eb-5a5e-51b7-a792-b248b319de09
DOI
10.1182/blood-2020-136872
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid LeukemiaDOI 10.1182/blood-2020-136872
Select a neighboring publication to make it the new centre.